Skip to content
Sept 4, 2021
Treating Cancer with Novel Synthetic Lethal Therapies
July 23, 2021
Mini-library Approach Delivers an Arsenal in Drug Development Pipeline
July 14, 2021
Anticancer Bioscience appoints Dr. Hong Liu, as US-based VP of clinical development
July 14, 2021
ACB hires Liu from Eureka Therapeutics to lead push into clinic
June 14, 2021
Anticancer Bioscience: applying synthetic lethality to MYC-driven cancers
June 7, 2021
Dun Yang – President & CEO, Anticancer Bioscience
March 25, 2021
Synthetic lethal drugs vs. cancer
February 9, 2021
Anticancer Bioscience Raises $10M to Advance Synthetic Lethality Programs
February 9, 2021
China’s Anticancer Bioscience raises $10 million, aims high in China
February 8, 2021
Anticancer Bioscience announces $10 million financing
February 08, 2021
A synthetic lethality player emerges in China, armed with lessons on undruggable oncogene from Nobel laureate's lab
